Precision Medicine and Molecular Testing in Oncology: How Personalized Cancer Treatment Works

Precision medicine and molecular testing have changed how specialists diagnose and treat cancer. This episode explains how genetic information, targeted therapies, and liquid biopsies help create personalized cancer treatment plans.

• How precision medicine personalizes cancer care
• What molecular and genomic profiling can reveal
• How targeted therapies attack specific cancer mutations
• Why liquid biopsy may help monitor treatment response
• How biomarker testing guides treatment choices
• Which cancers benefit from precision oncology
• How repeat testing can identify treatment resistance

Learn how precision oncology helps specialists select more effective treatments, reduce unnecessary side effects, and adapt care as cancer changes.

Blog Link: How oncology has evolved with precision medicine and molecular testing

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.

Transcript

SPEAKER_00 0:00

Welcome to the Onko Life Center podcast. So for decades, I mean, treating cancer was fundamentally uh basically an educated guessing game.

SPEAKER_01 0:09

Oh, completely. It was very trial and error.

SPEAKER_00 0:11

Right. Patients were given these highly toxic systemic chemicals, and the clinical approach was essentially, you know, to just wait and see who won the treatment or the tumor.

SPEAKER_01 0:21

Yeah, which is a brutal way to approach medicine.

SPEAKER_00 0:25

It really is.

SPEAKER_01 0:25

Yeah.

SPEAKER_00 0:26

But today, that guessing game is rapidly coming to an end. We are taking the black box of oncology and honestly blowing it wide open.

SPEAKER_01 0:34

We really are. The shift is massive. Trevor Burrus, Jr.

SPEAKER_00 0:36

And that's our mission for this deep dive. We're going to explore this rapid, groundbreaking evolution of cancer care, specifically looking through the lens of precision medicine and molecular testing.

SPEAKER_01 0:46

Aaron Powell, which is such a fascinating area right now.

SPEAKER_00 0:48

It is. And to do this, we're drawing our insights today from a really comprehensive clinical overview by Dr. Christina Eng, alongside the actual operational framework of the Onko Life Center in Kuala Lumpur.

SPEAKER_01 1:00

Right, getting both the theory and the real-world application.

SPEAKER_00 1:02

Aaron Powell Exactly. So if you, the listener, are navigating a diagnosis, or maybe you're advocating for a family member, or even if you're just tracking the cutting edge of human health, understanding this paradigm shift from treating the anatomy to treating the biology is, well, it's the ultimate shortcut to making empowered health care decisions.

SPEAKER_01 1:22

Aaron Powell It really is an inversion of how we've historically approached the disease. I mean, we used to categorize cancer purely by geography.

SPEAKER_00 1:29

Aaron Ross Powell By geography, like where it is in the body.

SPEAKER_01 1:31

Aaron Powell Exactly. We called it lung cancer or breast cancer. And then we applied a standard organ-specific protocol. But now we recognize that a lung cancer in one patient can be biologically completely different from a lung cancer in another patient.

SPEAKER_00 1:45

Aaron Ross Powell Wow. Okay. So location is kind of secondary now.

SPEAKER_01 1:48

Aaron Ross Powell Yeah. The geography matters far less than the underlying molecular machinery that's actually driving the tumor's growth.

SPEAKER_00 1:54

Aaron Ross Powell You know, reading through Dr. Christina Eng's overview, the distinction between the old way and the new way, it feels a lot like uh buying a suit.

SPEAKER_01 2:02

Aaron Ross Powell Buying a suit? I like that. How so?

SPEAKER_00 2:04

Aaron Ross Powell Well, traditional chemotherapy is a bit like buying an off-the-rack suit. Like it's a standard size, and you just hope it fits well enough to do the job without being incredibly uncomfortable.

SPEAKER_01 2:15

Right, right. It's a generalized approach.

SPEAKER_00 2:17

Yeah. But precision medicine is like getting a completely bespoke custom-tailored suit based on your exact specific measurements. It's made for you and only you.

SPEAKER_01 2:28

That's a really great analogy.

SPEAKER_00 2:29

Thanks. But it did make me wonder how do doctors actually get the measurements for this custom treatment? Because that introduces two terms that I think get super conflated in the public sphere, which are precision medicine and personalized medicine.

SPEAKER_01 2:43

Aaron Powell Oh, absolutely. They get tossed around interchangeably all the time. But um, Dr. Eng makes a really vital separation between the two in her framework.

SPEAKER_00 2:51

Aaron Powell Okay, break that down for us. What's the difference?

SPEAKER_01 2:53

So precision medicine is the hard data. It's the highly technical practice of analyzing a patient's specific cancer genes to find the exact mutations making that tumor grow.

SPEAKER_00 3:03

Aaron Powell Okay, so just focusing on the biology.

SPEAKER_01 3:06

Right. Purely the biological and genomic realities of the disease. Aaron Powell Now, personalized medicine is the broader clinical application. It takes that hard genetic data from precision medicine and layers it with, you know, the patient's overall health profile, their personal preferences, and their lifestyle.

SPEAKER_00 3:23

Oh, I see. So the precision aspect gives you the genetic target, but the personalized aspect determines how you actually execute the treatment plan for that specific human being.

SPEAKER_01 3:33

You nailed it. For example, if the precision data suggests a highly effective oral medication, but uh the personalized data shows the patient has severe absorption issues in their gut.

SPEAKER_00 3:43

Like they literally can't digest the pill properly.

SPEAKER_01 3:45

Exactly. Then the clinical team has to pivot. They might look for an intravenous option instead, just to ensure the drug actually reaches the bloodstream. The data always has to be filtered through the reality of the patient.

SPEAKER_00 3:56

Aaron Powell That makes so much sense. But going back to getting those measurements, how do oncologists actually get that hard precision data in the first place?

SPEAKER_01 4:04

Aaron Powell Well, they rely on some pretty advanced diagnostic tools. The foundational step is something called molecular profiling.

SPEAKER_00 4:10

Molecular profiling, okay.

SPEAKER_01 4:12

Yeah. This involves extracting DNA or RNA from a sample of the tumor and then using specialized lab techniques to look for specific known genetic mutations that are frequently associated with that type of cancer.

SPEAKER_00 4:24

Aaron Powell Got it. So it sounds kind of like running a targeted search on your computer for a specific virus signature. Like if a patient has lung cancer, the pathologists are just actively scanning the DNA for the specific biological typos that typically cause lung tissue to go rogue.

SPEAKER_01 4:40

Yes, that's exactly it. But I will say oncology is increasingly moving toward an even broader diagnostic tool, which is genomic profiling.

SPEAKER_00 4:48

Wait, how is that different from molecular profiling?

SPEAKER_01 4:50

Well, instead of just looking for a handful of common mutations, genomic profiling uses next generation sequencing, or NGS. And NGS analyzes thousands of genes all at the exact same time.

SPEAKER_00 5:01

Thousands, wow.

SPEAKER_01 5:02

Yeah. It isn't just looking for a single misspelled word in the code, it is analyzing the entire software architecture of the tumor.

SPEAKER_00 5:08

Aaron Powell That is wild.

SPEAKER_01 5:10

It really is. It searches for deleted genes, extra copies of genes, and even these massive structural rearrangements where entire sections of DNA have just broken off and attached somewhere else entirely. It essentially provides this comprehensive map of the tumor's evolutionary advantages.

SPEAKER_00 5:26

Aaron Powell Okay, so once you have that massive comprehensive map generated, transitioning from diagnosis to active treatment relies heavily on targeted therapies.

SPEAKER_01 5:36

Yes, very heavily.

SPEAKER_00 5:37

And the common analogy in the sources is the lock and key. But diving into the actual mechanics of it, it's clearly way more dynamic than just a piece of metal turning a tumbler. We're really talking about cellular signaling pathways, right?

SPEAKER_01 5:50

Aaron Powell Yes, that is a much more accurate way to look at it. Because healthy cells, they only divide when they receive a specific chemical signal telling them to do so.

SPEAKER_00 5:59

Right. They need permission.

SPEAKER_01 6:00

Exactly. But in cancer cells, a genetic mutation often acts like a switch that is permanently jammed in the on-end position.

SPEAKER_00 6:06

Aaron Powell Oh, so it's just constantly flooding the cell with signals to divide and multiply.

SPEAKER_01 6:11

Precisely. And that's where targeted therapies come in. They are these highly engineered molecules designed to physically bind to that specific mutated switch and just jam the mechanism. It effectively cuts the power cord to the cell's growth cycle.

SPEAKER_00 6:24

Aaron Powell And because that specific mutated switch doesn't even exist on healthy cells, targeted therapy largely just bypasses the rest of the body.

SPEAKER_01 6:32

Aaron Powell Exactly, which drastically reduces the collateral damage. We see this heavily referenced in lung cancer treatments within the text. I mean, mutations in genes like EGFR and ALK used to represent incredibly bleak prognoses.

SPEAKER_00 6:46

Yeah, those used to be devastating to find.

SPEAKER_01 6:48

They were. But today, if a lung cancer patient's genomic profile reveals an EGFR mutation, the standard of care is not blanket chemotherapy anymore. It's not. No. The patient is prescribed an EGFR inhibitor. It's a small molecule drug that literally enters the cancer cell, physically blocks the tyrosine kinase domain of the EGFR protein, and shuts down that whole signaling cascade.

SPEAKER_00 7:11

So the tumor is basically starved of its growth signal and begins to shrink.

SPEAKER_01 7:15

Right. And the patient is spared the widespread toxicity of traditional chemo. We apply similar principles in breast cancer too. Like when a tumor is HER2 positive, we use monoclonal antibodies that seek out those specific receptors.

SPEAKER_00 7:28

That is just incredible. Now, the section in Dr. Eng's clinical overview that really highlights the sophisticated nature of this profiling actually centers around colorectal cancer, specifically involving the KRAS mutation.

SPEAKER_01 7:42

Oh yes. The KRAS example is brilliant.

SPEAKER_00 7:44

Right. Because I think the intuitive assumption for most people is that we sequence DNA to find the miracle drug that will work. But the KRAS example demonstrates that genomic profiling is equally crucial for discovering what drugs absolutely won't work.

SPEAKER_01 7:59

I'm so glad you brought that up because this is honestly one of the most important clinical victories of molecular testing. To understand why, you have to look at the signaling pathway like a communication wire.

SPEAKER_00 8:09

Okay, picture a wire, got it.

SPEAKER_01 8:10

Right. So in some colorental cancers, doctors can use a biologic drug designed to block a receptor on the surface of the cell. Think of it like blocking the satellite dish that's receiving the signal.

SPEAKER_00 8:20

Sure. Block the dish, stop the signal.

SPEAKER_01 8:22

But the KRAS protein is located downstream inside the cell. It essentially acts as the wire connecting the satellite dish to the nucleus.

SPEAKER_00 8:30

Oh man. So if the KRAS gene is mutated, the wire inside the cell is just sparking and sending the growth signal entirely on its own, regardless of what the satellite dish on the outside is doing.

SPEAKER_01 8:41

Exactly. You've got it. So if a patient has a mutated KRAS gene, giving them a drug that blocks the outside receptor is completely useless. The signal is already bypassing it entirely.

SPEAKER_00 8:52

Wow. So without molecular profiling, an oncologist might prescribe that biologic drug, and the patient would spend, what, months enduring severe side effects and financial toxicity for a treatment that was biologically doomed to fail from day one.

SPEAKER_01 9:06

Exactly. Precision oncology prevents that waste of time. It dictates the exclusions just as much as the inclusions.

SPEAKER_00 9:12

But looking at the mechanics of this, I have to ask a probing question here. There seems to be a clear vulnerability in this system.

SPEAKER_01 9:17

Okay, what are you thinking?

SPEAKER_00 9:19

If we introduce a targeted therapy, like a drug perfectly designed to block a specific mutated receptor, we are introducing massive selective pressure on that tumor. And tumor cells are highly unstable, meaning they mutate rapidly. So aren't we essentially forcing microscopic Darwinian evolution? Like, does the lock actually change its shape?

SPEAKER_01 9:42

That is such a fantastic question. And you are describing the absolute greatest hurdle in modern oncology right now, which is treatment resistance.

SPEAKER_00 9:49

So it does change shape.

SPEAKER_01 9:50

Yes. A targeted therapy might successfully wipe out, say, 99% of the cancer cells carrying that specific mutation, but within that tumor, there may be a tiny subclone of cells that have acquired a completely new secondary mutation.

SPEAKER_00 10:04

Let me guess the current targeted drug cannot bind to this new structural alteration.

SPEAKER_01 10:09

Exactly. So that 1% of resistant cells survive the treatment, they multiply, and they repopulate the tumor with this new drug-resistant biology, the cancer essentially becomes a moving target.

SPEAKER_00 10:19

Man, that is terrifying.

SPEAKER_01 10:20

It is challenging. And because the biology of the tumor changes over time, our diagnostic approach has to adapt with it. Relying on the genetic data from a biopsy taken six months ago is essentially fighting a ghost. Exactly. But historically, this created a massive bottleneck for us. Traditional tissue biopsies require surgical intervention or invasive needle core extractions.

SPEAKER_00 10:46

And you obviously can't subject a patient to surgery every single time you suspect the tumor might be evolving.

SPEAKER_01 10:51

Right. It's just not physically or practically possible.

SPEAKER_00 10:53

Aaron Powell Which brings us to liquid biopsies. This blew my mind. Instead of surgically excising tissue to see how a tumor is mutating, the text details how oncologists can now just catch the genetic debris the tumor leaves behind in the bloodstream.

SPEAKER_01 11:07

It is a remarkable technological leap. Basically, as tumors grow rapidly, they often outpace their own blood supply.

SPEAKER_00 11:13

Aaron Powell Okay, so they grow too fast to feed themselves.

SPEAKER_01 11:15

Yes. As a result, cancer cells on the periphery of the tumor die and rupture. And when they burst, they shed their fragmented DNA directly into the patient's circulatory system.

SPEAKER_00 11:25

Aaron Powell So there's just tumor DNA floating in the blood.

SPEAKER_01 11:28

Right. We call this cell-free circulating tumor DNA or ET DNA. So a liquid biopsy is, from the patient's perspective, literally just a standard blood draw.

SPEAKER_00 11:37

Just a needle in the arm.

SPEAKER_01 11:38

Just a needle in the arm. But in the lab, next generation sequencing is used to isolate those microscopic fragments of tumor DNA from the billions of normal blood cells.

SPEAKER_00 11:49

That is amazing. That allows oncologists to sequence the tumor's current genome without ever touching the tumor itself. You can monitor the disease dynamics in near real time. Exactly. Like if the concentration of tumor DNA in the plasma is dropping, you know the targeted therapy is working. But if the DNA level spike, or if the sequencer detects a brand new mutation, the clinical team knows the tumor is evolving resistance before it ever even shows up as a growing mass on a CT scan.

SPEAKER_01 12:17

Which is huge. It allows for proactive switching of therapies rather than reactive scrambling.

SPEAKER_00 12:22

But I gotta play devil's advocate here based on the text. If liquid biopsies are just a simple blood test and avoid all that surgery, why on earth do we still use traditional tissue biopsies? Shouldn't liquid biopsies just replace them entirely by now?

SPEAKER_01 12:36

That is a very common question, but it's crucial to understand the limitations of liquid biopsies. The accuracy of a liquid biopsy is directly tied to the patient's tumor burden.

SPEAKER_00 12:47

Tumor burden, meaning the physical volume of active cancer in the body.

SPEAKER_01 12:51

Correct. If the tumor is very small or if it's super early stage, it simply isn't shedding enough dead cells into the bloodstream to cross the detection threshold of the sequencing equipment.

SPEAKER_00 13:02

Ah, okay. So it's there, but the machine just can't hear it over the noise.

SPEAKER_01 13:06

Exactly. If there isn't enough Ct DNA in the sample, the sequencer will return a negative result, even though the cancer is physically present. That false negative risk is why liquid biopsies have not replaced traditional tissue biopsies entirely.

SPEAKER_00 13:20

So they are basically used as a highly sophisticated monitoring tool alongside traditional testing rather than a total replacement.

SPEAKER_01 13:27

Yes, especially for tracking resistance and advanced disease stages, they are brilliant, but we still need tissue biopsies for that initial definitive diagnosis.

SPEAKER_00 13:36

Making sense. Now, up to this point, we've been focusing entirely on tracking mutations that occur spontaneously within tumor cells, uh somatic mutations. Right. But Dr. Eng's overview also heavily addresses the mutations we are born with. These are the germline mutations that dictate a patient's inherited risk long before a tumor ever even begins to form.

SPEAKER_01 13:58

This is a huge shift in the conversation.

SPEAKER_00 14:00

It really is. It moves us from targeted treatment to true prevention and risk management.

SPEAKER_01 14:05

And cancer gene testing for inherited risk is a deeply complex pillar of precision medicine. I mean, the most widely recognized examples are the BRCA1 and BRCA2 gene mutations.

SPEAKER_00 14:15

Aaron Powell Right. The ones that drastically increase the lifetime risk of developing breast and ovarian cancers. And the critical distinction the text makes here, and I think this is incredibly reassuring and important for anyone listening who might be looking at a genetic test result, is that a positive result for an inherited mutation indicates a high probability of risk. It is absolutely not a definite cancer diagnosis.

SPEAKER_01 14:36

Aaron Powell Yes, thank you for emphasizing that. It is a forecast, not a guarantee. And conversely, a negative result provides significant relief, indicating the patient likely does not carry that specific familial mutation.

SPEAKER_00 14:50

Aaron Ross Powell But still, navigating the implications of a positive result carries immense psychological weight. I mean, patients are suddenly burdened with the knowledge of a severe looming threat.

SPEAKER_01 14:59

It is terrifying data to receive. And this is why the integration of genetic counselors is non-negotiable in this framework. Aaron Powell Right.

SPEAKER_00 15:07

They don't just hand over a lab report and wish you large.

SPEAKER_01 15:09

No, not at all. Genetic counselors are specifically trained to translate this highly complex data into actionable, practical reality. They guide patients through the statistics, they outline proactive surveillance strategies like highly frequent MRIs, and they discuss the viability of prophylactic surgeries.

SPEAKER_00 15:26

And perhaps most importantly, they help patients navigate the cascade testing of their families, right? Because an inherited mutation has direct implications for siblings and children.

SPEAKER_01 15:36

It absolutely does. It requires an extraordinary level of empathetic, precise communication. And actually, this highlights a much broader reality about precision medicine as a whole. It cannot be executed in a vacuum.

SPEAKER_00 15:49

What do you mean by that?

SPEAKER_01 15:51

Well, you can sequence a genome and identify the perfect targeted therapy, but if you do not have the physical infrastructure and the clinical environment to safely deliver that care, the data is basically useless.

SPEAKER_00 16:02

Oh, right. Which bridges perfectly into the actual operational environment detailed in our sources, the Onko Life Center in Kuala Lumpur.

SPEAKER_01 16:11

Exactly.

SPEAKER_00 16:11

Reading through their clinical framework, it really grounds all of this abstract science into physical delivery. A key component of their facility that caught my eye is the cytotoxic drug reconstitution, or CDR complex.

SPEAKER_01 16:23

Yes, the CDR complex is vital.

SPEAKER_00 16:25

Aaron Powell Because when we talk about these advanced chemotherapies and targeted agents, we are often talking about highly volatile, hazardous biological compounds.

SPEAKER_01 16:33

They are incredibly potent medications. You cannot just prepare a targeted biologic or a complex chemotherapy regimen on a standard pharmacy countertop.

SPEAKER_00 16:43

I would imagine not.

SPEAKER_01 16:44

No, these drugs require a heavily controlled, sterile environment with negative pressure isolators. And that's to protect both the integrity of the medication and the safety of the clinical staff handling it.

SPEAKER_00 16:55

And I imagine the dosing has to be insanely precise.

SPEAKER_01 16:58

Oh, it's precision engineered down to the milligram. It's calculated against the patient's specific metabolic profile, their body surface area, and of course their genomic data.

SPEAKER_00 17:08

And the text notes that the CDR complex at Oncoll Life Center is operated by highly specialized pharmacy personnel, and it's certified by the National Pharmaceutical Regulatory Agency of the Ministry of Health in Malaysia.

SPEAKER_01 17:20

Which is a very rigorous standard to meet.

SPEAKER_00 17:22

It really represents the physical manifestation of precision, just ensuring the drug delivery is as exact as the DNA sequencing itself.

SPEAKER_01 17:29

And honestly, that level of comprehensive infrastructure is what drives international medical mobility today. When a facility successfully integrates advanced genomic sequencing, specialized genetic counseling, and state-of-the-art drug reconstitution all under one roof, it becomes a global hub for complex cases.

SPEAKER_00 17:48

The global reach they have is significant. The sources mention Onko Life Center provides care for patients traveling from Germany, Qatar, Bangladesh, Indonesia, Japan, and the UK.

SPEAKER_01 17:59

It's a true international destination.

SPEAKER_00 18:01

Yeah, people are crossing the globe for this specific intersection of high technology and rigorous clinical standards. And the center explicitly highlights empathy, dedication, professionalism, and quality as their core values.

SPEAKER_01 18:14

Aaron Powell Because when you are dealing with the raw biological reality of cancer, patients demand not just the most advanced technological tools, but a clinical environment that is wholly dedicated to the meticulous execution of those tools.

SPEAKER_00 18:28

Right. Technology dictates the capability, but the clinical environment dictates the outcome. The precision of the lab literally has to be matched by the precision of the care.

SPEAKER_01 18:36

Couldn't have said it better myself.

SPEAKER_00 18:38

So looking at the road ahead, Dr. Ng's overview outlines a future for precision oncology that is just accelerating exponentially.

SPEAKER_01 18:47

It is moving so fast.

SPEAKER_00 18:48

Sequencing costs are plummeting, the speed of analysis is increasing, we're moving rapidly toward a reality where comprehensive genomic profiling is just the standard baseline for every single patient upon diagnosis. But the variable that truly disrupts this field moving forward has to be the integration of artificial intelligence. I can't even imagine trying to read that.

SPEAKER_01 19:21

Right. And human researchers are brilliant, obviously, but they are limited by cognitive bandwidth. AI models, on the other hand, are being trained to ingest this massive genomic data and instantly identify minute patterns of mutation.

SPEAKER_00 19:34

So they can just flag the most viable targeted therapies out of millions of potential combinations in seconds.

SPEAKER_01 19:39

Exactly. AI is acting as the ultimate filter, cutting through the noise to find the actionable biological signal.

SPEAKER_00 19:45

It's incredible. So if you are listening to this and you or someone you love is facing a cancer diagnosis, the immediate takeaway is this the paradigm has completely shifted. You have the right to ask for the data. Absolutely. Advocate for yourself by asking your oncology team about molecular profiling and genomic testing right from the start. Ask them to map the biology of the tumor so you can find the specific treatment designed to stop it.

SPEAKER_01 20:13

Because understanding the molecular driver of the disease is unequivocally the most powerful weapon a patient can bring to a consultation today.

SPEAKER_00 20:20

Truly. Now, before we close out this deep dive, I want to leave you with one final thought to mull over. We know that tumors evolve under the pressure of targeted therapies, that microscopic Darwinian selection we talked about. Right. And we know that artificial intelligence is learning to recognize complex patterns in vast genomic data sets. So if we feed these AI models billions of data points on how specific mutations have historically evolved, could AI eventually predict a tumor's evolutionary trajectory before it even happens? Think about it. Could we one day sequence a tumor, predict exactly how it's going to mutate in six months, and prescribe a targeted therapy for a resistance mutation that hasn't even developed yet? We might soon be playing chess against cancer and finally thinking three moves ahead. Keep asking questions, keep advocating for the data, and we'll see you on the next deep dive.